Shenzhen New Industries Biomedical Engineering Co., Ltd.

XSEC:300832 Stock Report

Market Cap: CN¥55.3b

Shenzhen New Industries Biomedical Engineering Valuation

Is 300832 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300832 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300832 (CN¥70.4) is trading below our estimate of fair value (CN¥84.61)

Significantly Below Fair Value: 300832 is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300832?

Key metric: As 300832 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300832. This is calculated by dividing 300832's market cap by their current earnings.
What is 300832's PE Ratio?
PE Ratio29.9x
EarningsCN¥1.85b
Market CapCN¥55.31b

Price to Earnings Ratio vs Peers

How does 300832's PE Ratio compare to its peers?

The above table shows the PE ratio for 300832 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.9x
603658 Autobio Diagnostics
20.3x20.8%CN¥25.8b
300595 Autek China
26.2x16.8%CN¥17.1b
600529 Shandong Pharmaceutical GlassLtd
19.5x18.4%CN¥17.2b
688016 Shanghai MicroPort Endovascular MedTech
21.7x18.8%CN¥14.2b
300832 Shenzhen New Industries Biomedical Engineering
29.9x21.7%CN¥55.3b

Price-To-Earnings vs Peers: 300832 is expensive based on its Price-To-Earnings Ratio (29.9x) compared to the peer average (21.9x).


Price to Earnings Ratio vs Industry

How does 300832's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300832 29.9xIndustry Avg. 35.0xNo. of Companies15PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300832 is good value based on its Price-To-Earnings Ratio (29.9x) compared to the CN Medical Equipment industry average (36.1x).


Price to Earnings Ratio vs Fair Ratio

What is 300832's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300832 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.9x
Fair PE Ratio31.5x

Price-To-Earnings vs Fair Ratio: 300832 is good value based on its Price-To-Earnings Ratio (29.9x) compared to the estimated Fair Price-To-Earnings Ratio (31.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300832 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥70.40
CN¥85.65
+21.7%
7.3%CN¥95.79CN¥76.67n/a9
Dec ’25CN¥65.37
CN¥85.82
+31.3%
7.1%CN¥95.79CN¥76.67n/a9
Nov ’25CN¥67.39
CN¥85.79
+27.3%
6.6%CN¥95.79CN¥79.22n/a8
Oct ’25CN¥81.96
CN¥83.00
+1.3%
7.6%CN¥95.86CN¥73.73n/a7
Sep ’25CN¥66.87
CN¥83.00
+24.1%
7.6%CN¥95.86CN¥73.73n/a7
Aug ’25CN¥62.70
CN¥84.90
+35.4%
6.0%CN¥95.86CN¥79.22n/a7
Jul ’25CN¥66.36
CN¥85.50
+28.8%
5.8%CN¥93.36CN¥79.22n/a7
Jun ’25CN¥75.72
CN¥85.50
+12.9%
5.8%CN¥93.36CN¥79.22n/a7
May ’25CN¥70.70
CN¥81.83
+15.7%
11.0%CN¥93.36CN¥64.00n/a6
Apr ’25CN¥67.93
CN¥81.87
+20.5%
14.7%CN¥98.15CN¥64.00n/a6
Mar ’25CN¥80.63
CN¥76.31
-5.4%
10.4%CN¥86.50CN¥64.00n/a6
Feb ’25CN¥70.17
CN¥76.31
+8.7%
10.4%CN¥86.50CN¥64.00n/a6
Jan ’25CN¥78.20
CN¥76.31
-2.4%
10.4%CN¥86.50CN¥64.00n/a6
Dec ’24CN¥72.61
CN¥73.23
+0.9%
6.4%CN¥79.00CN¥64.00CN¥65.376
Nov ’24CN¥67.93
CN¥72.67
+7.0%
6.2%CN¥79.00CN¥64.00CN¥67.397
Oct ’24CN¥63.52
CN¥70.19
+10.5%
4.5%CN¥74.83CN¥64.00CN¥81.967
Sep ’24CN¥63.31
CN¥70.19
+10.9%
4.5%CN¥74.83CN¥64.00CN¥66.877
Aug ’24CN¥55.31
CN¥71.94
+30.1%
5.7%CN¥78.45CN¥64.00CN¥62.708
Jul ’24CN¥59.00
CN¥70.77
+20.0%
5.0%CN¥74.98CN¥64.00CN¥66.367
Jun ’24CN¥59.62
CN¥70.90
+18.9%
5.3%CN¥74.98CN¥64.00CN¥75.726
May ’24CN¥52.88
CN¥70.90
+34.1%
5.3%CN¥74.98CN¥64.00CN¥70.706
Apr ’24CN¥61.17
CN¥70.31
+14.9%
7.1%CN¥76.45CN¥63.33CN¥67.936
Mar ’24CN¥59.42
CN¥69.41
+16.8%
7.2%CN¥76.45CN¥63.33CN¥80.635
Feb ’24CN¥57.25
CN¥68.77
+20.1%
7.2%CN¥76.45CN¥63.33CN¥70.175
Jan ’24CN¥50.14
CN¥69.00
+37.6%
8.0%CN¥76.45CN¥63.33CN¥78.204
Dec ’23CN¥48.03
CN¥69.00
+43.7%
8.0%CN¥76.45CN¥63.33CN¥72.614

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies